Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.67, No.6, p.1367–1372, 2020 |
||
Title: Quantitative analysis of 2-hydroxyglutarate as a controversial oncometabolite in malignant gliomas. | ||
Author: P. BYSTRICKÝ, I. KAŠUBOVÁ, R. RICHTEROVÁ, Z. LASABOVÁ, B. KOLAROVSZKI | ||
Abstract: There is a great effort to connect the accumulation of 2-hydroxyglutarate (2-HG) oncometabolite with cellular onco-epigenetic status and subsequently predict the prognoses of glioma patients. In this observational study, the concentrations of D- and L- 2-HG were determined in 57 tumor tissue samples of glioma patients (n = 57) WHO grade I through IV (astrocytoma, oligodendroglioma, secondary glioblastoma and glioblastoma multiforme) in vitro. Also, genetic mutation status on isocitrate dehydrogenase 1 and 2 (IDH 1/2) was determined from these samples. The objective of this study was to confirm or to reject the hypothesis of the direct correlation of 2-HG concentration in tumor tissue and the results from IDH 1/IDH 2 point mutation analyses. The concentrations of 2-HG were quantified using high sensitive HPLC and Q-TOF HRMS spectrometer setup. Concurrently, the genetic mutation analyses of both IDH 1 (cytosolic) and IDH 2 (mitochondrial) were performed by the isolation of tumor tissue DNA, PCR amplification, and subsequent Sanger forward sequencing. Our results indicate that there is no definite correlation between the two as we identified cases of glioma tumors with significantly increased concentration of one or both L- and D- 2-HG but no IDH 1/2 mutations (44% 2-HG positive cases). |
||
Keywords: 2-hydroxyglutarate; Krebs cycle; oncometabolite; malignant gliomas; WHO grade; astrocytoma; oligodendroglioma; glioblastoma multiforme; IDH mutations | ||
Published online: 27-Aug-2020 | ||
Year: 2020, Volume: 67, Issue: 6 | Page From: 1367, Page To: 1372 | |
doi:10.4149/neo_2020_200302N216 |
||
|
download file |
|